Projects per year
Fingerprint Dive into the research topics where Christopher Vinnard is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 12 Similar Profiles
Tuberculosis
Medicine & Life Sciences
Meningeal Tuberculosis
Medicine & Life Sciences
HIV
Medicine & Life Sciences
Infection
Medicine & Life Sciences
Latent Tuberculosis
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Pharmacokinetics
Medicine & Life Sciences
Isoniazid
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2014 2023
Detecting heteroresistant M. tuberculosis infections using SuperSelective PCR
8/1/19 → 7/30/21
Project: Research project
Tuberculosis
Polymerase Chain Reaction
Infection
Drug Resistance
Pharmaceutical Preparations
Urine Colorimetry for Tuberculosis Pharmacokinetics Evaluation in Children and Adults
9/24/18 → 8/31/23
Project: Research project
Colorimetry
Tuberculosis
Pharmacokinetics
Urine
ROC Curve
Rifampicin Malabsorption in HIV+ Patients: Mechanisms and Recovery after HAART
2/15/14 → 1/31/20
Project: Research project
Highly Active Antiretroviral Therapy
Rifampin
HIV
Tuberculosis
Botswana
Research Output 2008 2019
Adipose tissue regulates pulmonary pathology during TB infection
Ayyappan, J. P., Ganapathi, U., Lizardo, K., Vinnard, C., Subbian, S., Perlin, D. & Nagajyothi, J. F., Mar 1 2019, In : mBio. 10, 2, e02771-18.Research output: Contribution to journal › Article
Open Access
Mycobacterium tuberculosis
Adipose Tissue
Tuberculosis
Pathology
Lung
Attainment of target rifampicin concentrations in cerebrospinal fluid during treatment of tuberculous meningitis
Mezochow, A., Thakur, K. T., Zentner, I., Subbian, S., Kagan, L. & Vinnard, C., Jul 2019, In : International Journal of Infectious Diseases. 84, p. 15-21 7 p.Research output: Contribution to journal › Article
Open Access
Meningeal Tuberculosis
Rifampin
Cerebrospinal Fluid
Microbial Sensitivity Tests
Therapeutics
8
Citations
(Scopus)
Dual β-lactam combinations highly active against mycobacterium abscessus complex in vitro
Pandey, R., Chen, L., Manca, C., Jenkins, S., Glaser, L., Vinnard, C., Stone, G., Lee, J., Mathema, B., Nuermberger, E. L., Bonomo, R. A. & Kreiswirth, B. N., Jan 1 2019, In : mBio. 10, 1, e02895-18.Research output: Contribution to journal › Article
Open Access
Lactams
Ceftazidime
Mycobacterium
Imipenem
Anti-Bacterial Agents
Guidelines-based treatment associated with improved economic outcomes in nontuberculous mycobacterial lung disease
Marras, T. K., Mirsaeidi, M., Vinnard, C., Chan, E. D., Eagle, G., Zhang, R., Wang, P. & Zhang, Q., Nov 2 2019, In : Journal of Medical Economics. 22, 11, p. 1126-1133 8 p.Research output: Contribution to journal › Article
Open Access
Lung Diseases
Economics
Guidelines
Health Expenditures
Therapeutics
Optimizing ethambutol dosing among HIV/tuberculosis co-infected patients: a population pharmacokinetic modelling and simulation study
Mehta, K., Ravimohan, S., Pasipanodya, J. G., Srivastava, S., Modongo, C., Zetola, N. M., Weissman, D., Ivaturi, V., Gumbo, T., Bisson, G. P. & Vinnard, C., Oct 1 2019, In : The Journal of antimicrobial chemotherapy. 74, 10, p. 2994-3002 9 p.Research output: Contribution to journal › Article
Ethambutol
Tuberculosis
Pharmacokinetics
HIV
Population